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IL-10 is a potent anti-inﬂammatory molecule that, in phagocytes,
negatively targets cytokine expression at transcriptional and post-
transcriptional levels. Posttranscriptional checkpoints also represent
the speciﬁc target of a recently discovered, evolutionary conserved
class of small silencing RNAs known as “microRNAs” (miRNAs),
which display the peculiar function of negatively regulating mRNA
processing, stability, and translation. In this study, we report that
activation of primary human monocytes up-regulates the expres-
sion of miR-187 both in vitro and in vivo. Accordingly, we identify
miR-187 as an IL-10–dependent miRNA playing a role in IL-10–medi-
ated suppression of TNF-α, IL-6, and the p40 subunit of IL-12 (IL-
12p40) produced by primary humanmonocytes following activation
of Toll-like receptor 4 (TLR4). Ectopic expression of miR-187 consis-
tently and selectively reduces TNFα, IL-6, and IL-12p40 produced by
LPS-activatedmonocytes. Conversely, the production of LPS-induced
TNF-α, IL-6, and IL-12p40 is increased signiﬁcantly when miR-187
expression is silenced. Our data demonstrate that miR-187 directly
targets TNF-αmRNA stability and translation and indirectly decreases
IL-6 and IL-12p40 expression via down-modulation of IκBζ, a master
regulator of the transcription of these latter two cytokines. These
results uncover an miRNA-mediated pathway controlling cytokine
expression and demonstrate a central role of miR-187 in the physio-
logical regulation of IL-10–driven anti-inﬂammatory responses.
The correct evolution of inﬂammation is under the control ofseveral mechanisms whose loss predisposes to a number of
inﬂammation-driven pathologies (1, 2). For instance, over-
whelming immune activation is prevented mainly by inhibition of
proinﬂammatory cytokines and chemokines, produced by innate
immune cells via activation of Toll-like receptors (TLRs). One of
the most effective suppressors of TLR-induced inﬂammatory
cytokine production is IL-10, which displays powerful inhibitory
actions on innate immune cell activation (3). IL-10 repressive
activity on cytokine production can be achieved not only by di-
rectly inhibiting gene transcription (4, 5) but also by destabilizing
mRNA or by blocking translation (6). With respect to these two
latter points, microRNAs (miRNAs) are increasingly attractive
molecules for their ability to function as posttranscriptional in-
hibitors and, in the context of inﬂammation, for their active role in
regulating the strength and timing of TLR responses (7).
miRNAs constitute a class of small, noncoding RNAs that target
coding RNA and silence them. miRNA expression is regulated ﬁrst
by transcription factors and RNA polymerase II (Pol II) that
generate primary miRNAs (pri-miRNA), which subsequently are
cleaved by two different RNase III to produce a mature 21- to
23-nt dsRNA duplexes (8). One strand of the mature miRNA is
used as a template to identify target mRNAs. Binding of the
miRNA guide strand to the “miRNA recognition element” within
the 3′ UTR of target mRNA leads to repression of translation and,
eventually, to mRNA destabilization and degradation (9). miRNAs
have been demonstrated to be fundamental as transcription factors
in the execution of several physiological, developmental, and re-
active programs, including the immune response (10). In fact, ac-
tivation of inﬂammatory cells via TLRs triggers the expression of
several miRNAs, which, in turn target different components of the
TLR signaling itself, ﬁne-tuning the overall response (7). For in-
stance, the TLR-responsive miR-146a negatively regulates TLR
activation by targeting key signaling proteins, such as IL-1R–asso-
ciated kinase 1 (IRAK1) and TNF receptor–associated factor 6
(TRAF6) (11), thus fulﬁlling an anti-inﬂammatory role. On the
other hand, miR-9, similarly induced by TRL2/4 activation in hu-
man neutrophils and monocytes, represses the expression of NF-κB
p50, in this way conditioning the type and the activity of the
downstream NF-κB transcriptional activator (12). However, be-
cause one single miRNA can have several target genes, there
are cases in which the role of a given miRNA in regulating in-
ﬂammation is not immediately evident. This is the case of miR-155,
which has been shown to target either activators of TLR signaling,
such as the myeloid differentiation primary-response protein 88
(MyD88) (13, 14) and TAK1-binding protein 2 (TAB2) (15), or
inhibitors of TRL signal propagation, such as the SH2 domain-
containing inositol-5′-phosphatase 1 (SHIP1) (16) and the sup-
pressor of cytokine signaling 1 (SOCS1) (17). Thus, given the
importance of miRNAs in the modulation of TLR signaling, it is
conceivable that anti-inﬂammatory stimuli can either increase or
suppress miRNA expression, according to their role in sustaining
or repressing TLR-mediated cell activation. Remarkably, IL-10 has
been shown recently to inhibit miR-155 induction by TLRs and, as
a consequence, to reverse miR-155–mediated down-regulation of
SHIP1, a validated target of miR-155 (18), which has been shown
in another context to affect TLR signaling events (19).
Recently we have shown that LPS induces the expression of
a distinct set of miRNAs in primary human monocytes (12). With
the aim of identifying whether some of the anti-inﬂammatory
functions of IL-10 are achieved via modulation of miRNAs, we
analyzed the effect of IL-10 on the miRNA proﬁle induced by
TLR4 activation. Here we demonstrate that IL-10, simulta-
neously added to or endogenously produced by LPS-stimulated
cells, down-modulates the expression of LPS-induced miR-155,
while it rapidly and transiently enhances LPS-induced miR-146b
expression. Most importantly, we identiﬁed miR-187 as a direct
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target of IL-10 and provide experimental validation of miR-187
target genes, revealing previously uncovered mechanisms trig-
gered by IL-10 to inhibit LPS-induced TNF-α, IL-6, and IL-
12p40 production. Thus, this study identiﬁes miR-187 as an
IL-10–dependent miRNA with a speciﬁc anti-inﬂammatory role.
Results
IL-10 Mediates the Induction of miR-187 Expression. In our previous
work we described the involvement of miRNAs in the regulation
of monocyte activation after TLR engagement (12). We extended
this study and investigated whether miRNAs play an active role
also in IL-10–mediated suppression of monocyte activation. Taq-
Man–based low-density miRNA array showed that stimulation of
freshly puriﬁed monocytes with IL-10 increases the expression of
miR-146b and miR-187 but not of any of the other 356 miRNAs
analyzed (Fig. 1A). Moreover, simultaneous addition of IL-10 to
LPS-stimulated monocytes enhances the induction of LPS-in-
duced miR-146b and miR-187 expression but not that of the other
LPS-induced miRNAs (Fig. 1B and Table S1). Additionally, and
in line with recent observations in bone marrow-derived mouse
macrophages (18), IL-10 inhibits the expression of LPS-induced
miR-155 (Fig. 1B). The ability of IL-10 to induce miR-146b and
miR-187 expression directly was conﬁrmed in a time-course
analysis (Fig. 1C). On the other hand, the increase in miR-146b
expression in monocytes treated with LPS plus IL-10 is transient,
because it starts to be detectable at 2 h but is not distinguishable
from that induced by LPS alone at 24 h (Fig. 1C). In contrast, the
potentiating effect of IL-10 on LPS-induced miR-187 expression
starts to be detectable after 2 h and is maintained up to 24 h (Fig.
1C). These data point to miR-187 as the main LPS-induced
miRNA strongly up-regulated by IL-10.
In human monocytes LPS stimulates IL-10 production, which
in turn acts on monocytes in an autocrine manner (20). To in-
vestigate whether endogenously produced IL-10 plays a role in
the expression of miR-187 induced by LPS, monoclonal anti–IL-
10 antibodies (or isotype-speciﬁc control IgG) were added to
monocytes, and the expression levels of miR-187 were analyzed
24 h after LPS stimulation (Fig. 1D). We found that the in-
duction of miR-187 by LPS is reduced by 70.6% in the presence
of IL-10–blocking antibodies, but miR-146b induction is not
affected (Fig. 1D and Table S2).
The expression of miR-187 then was evaluated in monocytes,
monocyte-derived macrophages (MDM), and autologous poly-
morphonuclear cells(PMN) stimulated with LPS or LPS plus
IL-10 for 24 h (Fig. 2A). Consistent with a potential role for IL-10
in LPS-induced miR-187 expression, LPS is able to trigger the
expression of miR-187 in monocytes and MDM but not in PMN
(Fig. 2A), which do not produce IL-10 upon LPS activation (21).
Conversely, addition of exogenous IL-10 to LPS-stimulated PMN
also restores the ability of these cells to up-regulate miR-187 ex-
pression (Fig. 2A), further suggesting that IL-10 is required for
LPS-induced miR-187 expression. Interestingly, the ability of LPS
and LPS plus IL-10 to up-regulate miR-187 expression is conﬁned
to peripheral blood myeloid cells of human origin and does not
apply to mononuclear cells of mouse origin. In fact, the expression
of miR-187 is not induced by LPS in thyoglicolate-elicited mac-
rophages (TEM) (Fig. S1A), in bone marrow-derived macro-
phages (BMDM) (Fig. S1B), or in the Raw264.7 macrophage cell
line (Fig. S1C), whereas expression of miR-155 or miR-146a is
observed readily (Fig. S1 A–C). Similarly, LPS plus IL-10 was un-
able to up-regulate the expression of miR-187 in all mouse mono-
nuclear cells tested (Fig. S1 D–F), which are perfectly responsive to
LPS and LPS plus IL-10, as assessed by modulation of CXCL10
expression (Fig. S1D–F). Up-regulation of miR-187 expression also
was observed in human monocytes challenged with palmitoyl-3-
cysteine-serine-lysine-4 (Pam3CSK4) and poly(I:C) (TLR2 and
Fig. 1. Modulation of miRNA expression by IL-10. Freshly puriﬁed monocytes were cultured for 8 h with 200 U/mL IL-10 or were left untreated (A) or were
treated with 100 ng/mL LPS alone or in combination with IL-10 (B). Changes in miRNA expression levels were determined using a microﬂuidic card. Results are
expressed as arbitrary units on a log scale using RNU44 as reference control. The mean values of two individual experiments performed are shown. Dotted
lines represent the two-fold and 0.5-fold boundary values for fold induction. (C ) Monocytes were cultured for the indicated times with LPS (—●—),
IL-10 (- - -▲- - -), or LPS plus IL-10 (- - -●- - -) or were left untreated (—▲—). The expression of miR-146b (Left) and miR-187 (Right) was analyzed by RT-qPCR in
triplicate samples and was normalized to the RNU44 levels. The results are expressed as fold change (FC) and are representative of three individual
experiments. (D) Monocytes were left untreated (-) (Left) or were stimulated with LPS alone or in the presence of 1 μg/mL blocking antibodies against IL-10 or
isotype control IgG2b, and the expression of miR-146b and miR-187 (Right) was determined 24 h after stimulation. Each graph represents the miRNA levels
determined by RT-qPCR and normalized to the RNU44 levels. Each panel shows one experiment representative of three performed with similar results.
E3102 | www.pnas.org/cgi/doi/10.1073/pnas.1209100109 Rossato et al.
TLR3 agonists, respectively) or with the proinﬂammatory cytokines
IL-1β and TNF-α at levels correlating with the amounts of IL-10
produced in response to the various stimuli (Fig. 2B). Pam3CSK4
and IL-1β up-regulated miR-187 expression, which in turn was
suppressed by the addition of anti-IL-10R antibodies (Fig. 2C),
suggesting that other monocyte-activating stimuli can trigger the
expression of miR-187, provided that they trigger IL-10 production.
Mature miR-187 is generated by processing a precursor
(premiR-187) transcribed from an intergenic region located on
chromosome 18. IL-10 rapidly increases LPS-induced premiR-
187 levels (Fig. 2D), suggesting that it exerts its up-regulatory
effect at the transcriptional level. In fact, as assayed byChIP, the
recruitment of Pol II to the genomic region encoding premiR-
187 in monocytes stimulated with LPS for 8 h is enhanced in the
presence of IL-10 and is inhibited in the presence of anti–IL-10
neutralizing antibodies (Fig. 2E).
Taken together, these data support a role for endogenous
IL-10 in LPS-induced miR-187 expression and, above all, call
attention to miR-187 as an miRNAthat is induced in an IL-10–
dependent manner.
miR-187 Plays a Functional Role in IL-10–Mediated Suppression of
LPS-Induced TNF-α, IL-6, and IL-12p40. To investigate whether the
expression of miR-187 was functionally involved in the production
of cytokine by LPS and in its regulation by IL-10, we inhibited
miR-187 by transiently transfecting monocytes with an miR-187-
speciﬁc ssDNA-locked nucleic acid (LNA) knockdown probe
(as-miR-187) or with a scramble miRNA knock-down probe (as-
miR-scr) as a control (Fig. S2). Transfected monocytes then were
stimulated with LPS or LPS plus IL-10 for 24 h, and the levels of
different cytokines and chemokines production were analyzed in
the cell-free supernatants (Fig. 3). miR-187 knockdown by as-
miR-187 signiﬁcantly increases TNF-α (P = 0.037), IL-6 (P =
0.040), and IL-12p40 (P = 0.037) production in response to LPS
(Fig. 3 A and C and Table S3). Most importantly, blocking miR-
187 induction partially, but signiﬁcantly, reversed IL-10–mediated
inhibition of LPS-induced TNF-α (P = 0.049), IL-6 (P = 0.038),
and IL-12p40 (P = 0.036) (Fig. 3 B and C and Table S3). On the
contrary, the production of other cytokines (IL-1β, IL-1ra, and
IFN-β) or chemokines (CXC10, CCL2, and CXL8) in response to
LPS and/or LPS plus IL-10 was unmodiﬁed in as-miR-187–
transfected monocytes compared with as-miR-scr–transfected cells
(Fig. S3), indicating that under these conditions the increased
TNF-α, IL-6, and IL-12p40 production is not the result of a gen-
eral effect of miR-187 down-modulation. Remarkably, miR-187
knockdown by as-miR-187 transfection does not modify LPS-in-
duced IL-10 production (Fig. S3), thus excluding a role for IL-10
in the increase in LPS-induced TNF-α, IL-6, and IL-12p40. Col-
lectively, these data indicate the induction of miR-187 as one of
the mechanisms used by IL-10 to suppress LPS-induced TNF-α,
IL-6, and IL-12p40 production.
Fig. 2. IL-10 is required for LPS-induced miR-187 expression. The expression
of miR-187 was determined by RT-qPCR in the following conditions. (A)
Monocytes, MDM, and autologous PMN were cultured for 24 h with LPS or
with LPS plus IL-10. (B) Monocytes were cultured in the presence of 100 ng/
mL Pam3CSK4, 50 μg/mL poly(I:C), 20 ng/mL IL-1β, or 5 ng/mL TNF-α for 24 h.
IL-10 content was determined by ELISA in cell-free supernatant of the same
samples and is plotted as function of the level of miR-187 expression. (C)
Monocytes were stimulated for 24 h with LPS, Pam3CSK4, or IL-1β in the
presence of 10 μg/mL anti–IL-10R antibody or IgG1K isotype control antibody.
(D) Monocytes were cultured for the indicated times with LPS or LPS plus IL-
10 or were left untreated, and the expression of premiR-187 was analyzed by
RT-qPCR. (E) Monocytes were left untreated or were stimulated with LPS in
the presence of control IgG2b antibody, anti–IL-10 antibody, or IL-10 for 8 h.
A ChIP assay was performed with anti-Pol II antibody and analyzed by qPCR
with primers amplifying the premiR-187 locus. Data from qPCR are expressed
as fold change (FC) over control sample as described in SI Materials and
Methods. Each panel shows one representative experiment of at least three
performed with similar results.
Fig. 3. Effect of miR-187 levels on LPS-induced cytokine release. Monocytes
from ﬁve different donors were transfected with as-miR-scr or as-miR-187
and 18 h later were stimulated with LPS (A) or with LPS plus IL-10 (B) for 24 h.
Cell-free supernatants were collected, and antigenic TNF-α, IL-6, and IL-
12p40 were quantiﬁed by ELISA. (C) The percent of variation (mean ± SEM,
n = 5) in cytokine release detected from monocytes transfected with as-miR-
187 vs. as-miR-scr control.
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TNF-α Is a Direct Target of miR-187. Based on the observation that
the levels of TNF-α, IL-6, and IL-12p40 production are increased
signiﬁcantly when the intracellular levels of miR-187 expression
are knocked down, we analyzed whether these cytokine genes are
direct targets of miR-187. MicroRNAs exert their biological
functions through the suppression of target genes via RNA–
RNA complementarity. Using a combination of Miranda and
TargetScan, we generated a list of 197 potential miR-187 targets,
among which only TNF-α, but not IL-6 or IL-12p40, was in-
cluded. Interestingly, kinetics of TNF-α mRNA expression in-
versely correlates with that of miR-187 in monocytes stimulated
with LPS and LPS plus IL-10 (Fig. S4A). To conﬁrm TNF-α
mRNA as a direct target of miR-187, reporter constructs con-
taining the renilla luciferase gene fused to the TNF-α 3′ UTR
(luc-TNF-α) or to a version of the TNF-α 3′ UTR deleted of the
miR-187 seed region (luc-mut-TNF-α) were transiently trans-
fected into HEK293 cells together with miR-187 mimics or
miR-scr. As shown in Fig. 4A, miR-187 signiﬁcantly reduced luc-
TNF-α, but not luc-mut-TNF-α, luciferase activity demonstrating
that the region located at nucleotides 1,273–1,282 of the TNF-α
cDNA and 31 nt upstream of the TNF-α AU-rich element is the
active seed of miR-187. Consistent with the luc-TNF-α reporter
results, a marked reduction in TNF-α production was observed
reliably in response to LPS (mean reduction 59.6 ± 5.6%; n = 5,
P = 0.028) and to LPS plus IL-10 (mean reduction 48.5 ± 5.7%;
n = 5, P = 0.005) in monocytes overexpressing the miR-187
mimic (Fig. S2B) compared with miR-scr (Fig. 4B and Table S3).
Under these conditions, the reduced amount of TNF-α protein
was paralleled by a comparable reduction in the levels of TNF-α
mRNA expression (−39.2%), but not of TNF-α primary tran-
scripts (Fig. S4B), further demonstrating that miR-187 directly
controls TNF-α gene expression at the posttranscriptional level.
In the attempt to investigate the mechanism whereby miR-
187 decreases TNF-α mRNA expression and production in
LPS-treated monocytes, we examined the effect of miR-187
overexpression on TNF-α mRNA stability. miR-187– or miR-
scr–transfected monocytes were stimulated with LPS for 90 min
and then were treated with actinomycin D to block the for-
mation of additional transcripts. At increasing intervals there-
after, cells were processed and changes in the amount of TNF-α
mRNA were quantiﬁed by RT quantitative PCR (RT-qPCR).
Fig. 4C shows that miR-187 overexpression markedly reduces
TNF-α half-life compared with miR-scr (33 min vs. 18 min).
This effect was speciﬁc for TNF-α, because miR-187 did not
signiﬁcantly modify the stability of IL-6 mRNA (Fig. 4C).
Collectively, these data demonstrate that miR-187 is part of the
IL-10–dependent mechanism that controls TNF-α expression at
a posttranscriptional level.
miR-187–Mediated Down-Regulation of IκBζ Sustains the Inhibitory
Effect of IL-10 on LPS-Induced IL-6 and IL-12p40 Production. To un-
derstand why miR-187 silencing modulates the production of IL-6
and IL-12p40 (Fig. 3), which are not listed among the 197 target
genes commonly predicted by Miranda and TargetScan algo-
rithms, additional criteria (as speciﬁed in Fig. S5A) were used to
identify miR-187 targets involved in the regulation of IL-6 and IL-
12p40 expression. Because many studies have highlighted the fact
that miRNA-mediated targeting of transcription factors, including
those activated upon TLR signaling (12, 22, 23), is an important
aspect of miRNA function (24–26), we focused on genes encoding
inﬂammation-related transcription factors and identiﬁed them by
Gene Ontology (GO)-terms association.
This analysis predicted the transcriptional regulators NFKBIZ,
BCL6, and SMAD1 as the most highly probable miR-187 target
genes (Fig. S5 A and B). Interestingly, NFKBIZ encodes for
a nuclear protein IκBζ, also known as “MAIL” (27), that is in-
duced upon TLR/IL-1R stimulation and that is required for the
LPS-dependent induction of IL-6 and IL-12p40 (27-29). Fur-
thermore, additional observations indirectly supported the pre-
diction of NFKBIZ as one of the most likely miR-187 target
genes. In fact, in a reverse analysis, miR-187 was identiﬁed by
both Miranda and TargetScan algorithms as being among the
NFKBIZ-targeting miRNAs with a favorable energy score (Fig.
S5C). Additionally, kinetics of expression of IκBζ (the NFKBIZ
protein product) inversely correlates with the expression of miR-
187 in monocytes stimulated with LPS (Fig. S5 D and E). This
inverse correlation is even stronger in monocytes stimulated with
LPS plus IL-10, in which miR-187 expression is potentiated but
the expression of IκBζ is further reduced, particularly at 12 and
24 h when this effect is the most pronounced (Fig. S5 D and E).
To test whether miR-187 posttranscriptionally affects NFKBIZ
expression, a reporter construct containing the renilla luciferase
gene fused to the NFKBIZ 3′ UTR (luc-NFKBIZ) (Fig. 5A) was
transiently transfected in HEK-293 cells together with miR-187
mimic. As shown in Fig. 5B, miR-187 signiﬁcantly reduced luc-
NFKBIZ luciferase activity by 29.74%. Deletion of the upstream
Fig. 4. TNF-α is a direct target of miR-187. (A) Base pairing comparison
between mature miR-187 and wild-type or mutant TNF-α 3′UTR putative
target site is shown according to the Miranda algorithm. The TNF-α 3′UTR-
luciferase construct was cotransfected in HEK293 cells with miR-187 mimic or
miR-scr. Relative renilla luciferase activity is expressed as mean ± SEM (n = 3),
adjusted to 1. *P < 0.01; ns: P > 0.05; Student t test; ns, not signiﬁcant. (B)
The amount of antigenic TNF-α was quantiﬁed by ELISA in cell-free super-
natants collected after 24 h from monocytes transfected with miR-187 mimic
or miR-scr and stimulated with LPS (Left) or LPS plus IL-10 (Center). (Right)
Percent of variation of TNF-α released by monocytes transfected with miR-
187 mimic vs. miR-scr control (mean ± SEM, n = 5). (C) Monocytes transfected
with miR-187 mimic or miR-scr control were cultured with LPS for 90 min
before the addition of 10 μg/mL actinomycin D (ActD). Monocytes were
harvested 20, 40, 70, and 90 min after the addition of actinomycin D (time 0),
and total RNA was puriﬁed and analyzed by RT-qPCR using speciﬁc primers
for TNF-α and IL-6 mRNA. Expression data are expressed as percent of mRNA
remaining at each time point vs. mRNA levels at time 0. Half-lives were
calculated by regression analysis. One experiment representative of two
performed is shown.
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1,111 bp of the NFKBIZ 3′UTR (luc-NFKBIZΔ1–1111), containing
an active miR-124 seed region (30), did not modify the miR-187–
mediated inhibition of luciferase activity, which instead was re-
versed by deletion of 5 bp in the miR-187 seed region (Fig. 5A) in
the NFKBIZ 3′ UTR (luc-mut-NFKBIZΔ1–1111) (Fig. 5B), dem-
onstrating the speciﬁcity of miR-187:NFKBIZ 3′ UTR interaction.
To provide direct evidence for NFKBIZ as a physiologic target
of miR-187, we tested whether miR-187 can inﬂuence the levels
of the endogenous IκBζ protein expression directly (Fig. 5 C–F).
An miR-187 mimic or a scramble negative control was tran-
siently transfected in monocytes (Fig. S6A), and the level of IκBζ
protein expression following LPS stimulation was assessed by
Western blotting (Fig. 5C). Three hours after LPS stimulation,
miR-187 overexpression leads to a reduction in the expression of
the IκBζ protein (Fig. 5C). The reduction of the IκBζ protein
content by miR-187 was reproduced consistently in four in-
dependent experiments, with a signiﬁcant (P = 0.001) mean
reduction of 19.8 ± 2.3% (Fig. 5D). In the complementary ap-
proach, we functionally inhibited miR-187 by transiently
transfecting monocytes with as-miR-187 or with the as-miR-scr
control (Fig. S6B). IκBζ protein levels were analyzed 6 h after
stimulation with LPS or with LPS plus IL-10, a time point at
which miR-187 induction is readily detectable (Fig. 1C). Si-
lencing miR-187 expression affects IκBζ protein levels (Fig. 5E),
which increase by 27.5 ± 0.35% and 43.3 ± 13.61% in monocytes
stimulated for 6 h with LPS and LPS plus IL-10, respectively
(Fig. 5F). Remarkably, blocking miR-187 induction by an
miRNA inhibitor partially reversed IL-10–induced inhibition of
IκBζ (Fig. 5 E and F).
To investigate whether the negative regulation of IκBζ by miR-
187 was functionally involved in the production of IL-6 and
IL-12p40 by LPS and in their regulation by IL-10, the effect of
miR-187 expression was compared with that of a speciﬁc siRNA
against IκBζ. Human monocytes were transfected with 50, 100, or
150 pmol of miR-187 mimic (Fig. S7A) or with 15, 50, or 150 pmol
of si-IκBζ (Fig. S7B), and the expression of IκBζ mRNA (Fig. S7
C and D) and protein (Fig. S7 E–H) was analyzed. As shown in
Fig. S7, although si-IκBζ decreased the levels of IκBζ mRNA in
a dose-dependent manner, miR-187 dose-dependently reduced
the expression of IκBζ protein but not IκBζ mRNA, suggesting
that it inhibits IκBζ translation. This effect was speciﬁc for IκBζ,
because miR-187 did not affect the expression of the IκBα protein,
a homolog of IκBζ (Fig. S7 E and I). In subsequent experiments,
150 pmol of miR-187 mimic or 15 pmol of si-IκBζ, which com-
parably reduced IκBζ protein expression by ∼30% (Fig. S7 E–H),
was transfected into monocytes (along with their related controls),
and the expression of IL-6 and IL-12p40 mRNA was analyzed
after 3 h of LPS stimulation (Fig. 6). The reduction of IκBζ ex-
pression mediated by either miR-187 or si-IκBζ causes a signiﬁ-
cant and comparable reduction of the transcriptional activation of
the IL-6 and IL-12p40 genes, as shown by the reduced recruitment
of Pol II to the IL-6 and IL-12p40 promoters (Fig. 6 A and B).
Moreover, LPS-induced IL-6 and IL-12p40 primary transcript are
reduced consistently in both miR-187– (Fig. 6C) and si-IκBζ–
Fig. 5. Modulation of IκBζ expression by miR-187. (A) The putative pairing
between miR-187:WT-NFKBIZ 3′UTR and miR-187:mut-NFKBIZ 3′UTR is shown.
(B) HEK293 cells were cotransfected with the luc-NFKBIZ full-length luciferase
or with the luc-NFKBIZ Δ1–1111 or the luc-mut-NFKBIZ Δ1–1111 construct
together with miR-187, miR-124, or miR-scr, as indicated. Relative luciferase
activity (relative luminescence units, RLU) is expressed as mean ± SEM (n = 4),
adjusted to 1. ***P < 0.001; ns, P > 0.05; Student t test or one-way ANOVAwas
used or the comparison between two or three groups, respectively). (C and
E) Freshly puriﬁed monocytes were transfected with 100 pmol miR-scr or
miR-187 mimic and were stimulated with LPS for 3 h (C) or were transfected
with 150 pmol as-miR-scr or as-miR-187 and were stimulated with LPS or LPS
plus IL-10 for 6 h (E). Total cell extracts (typically 100 μg) were loaded on gels,
and immunoblots were performed by simultaneously using antibodies spe-
ciﬁc for IκBζ and STAT3, followed by incubation with Alexa Fluor 680 goat
anti-rabbit and IRDyeTM 800 goat anti-mouse antibodies. One experiment
representative of three is shown in C and E. (D and F) Blots were scanned
with the Odyssey Infrared Imaging System. IκBζ levels quantiﬁed by the
Odyssey software and normalized for the total STAT3 are reported. Graphs
represent the mean ± SEM (n = 3); **P < 0.01; *P < 0.05; one-way ANOVA.
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(Fig. 6D) transfected monocytes. Consistently, LPS-induced IL-6
and IL-12p40 production is reduced signiﬁcantly in miR-187–
and si-IκBζ–transfected monocytes compared with their respective
controls (Fig. 6 E and F). Collectively, these data demonstrate
that IL-10, through the miR-187–mediated reduction of IκBζ,
indirectly inhibits LPS-induced IL-6 and IL-12p40 transcription
and production.
miR-187 and Its Target mRNAs Speciﬁcally Colocalize in Ago Complexes.
miRNA-target transcripts are recruited via miRNA–mRNA in-
teraction to the Argonaute (Ago)-containing RNA-induced si-
lencing complex (RISC) (31). To provide direct evidence that
miR-187 targets NFKBIZ and TNFA genes, we looked for the
presence of IκBζ and TNF-α mRNA in miR-187–containing RISC
complexes. Monocytes were incubated with or without LPS for
16 h, a time point at which high levels of endogenous miR-187 are
detected (Fig. 1C). In parallel, monocytes were transfected with
miR-187 mimic, along with miR-scr control, and were stimulated
for 2 h with LPS, a time point at which IκBζ and TNF-α mRNAs
are expressed at high levels but endogenous miR-187 expression
levels are only slightly above the control (Fig. 1C). Ago immuno-
precipitation was performed using a monoclonal antibody toward
all human Ago isoforms and was validated by Western blotting
(Fig. S8A). miR-187, TNF-α, and IκBζ mRNA levels then were
analyzed by RT-qPCR in the RNA fraction extracted from Ago
and IgG1κ immunoprecipitates. A signiﬁcant recruitment of miR-
187 to the Ago complexes was observed in LPS-stimulated (Fig. 7A)
and miR-187–overexpressing (Fig. 7B) monocytes compared with
resting and miR-scr–transfected monocytes, respectively. The lack
of miR-187 association with the Ago complexes in unstimulated
monocytes or in miR-scr–transfected monocytes was not caused by
a failure to immunoprecipitate Ago-bound miRNAs, as shown by
the detection in the same samples of a constitutively expressed
miRNA, i.e., miR-16 (Fig. S8 B and C), which occurs under resting
conditions and is not modiﬁed by LPS stimulation or by miR-187
overexpression. mRNAs encoding for IκBζ (Fig. 7C) and TNF-α
(Fig. 7E) are signiﬁcantly recruited to the Ago complexes upon
LPS stimulation, demonstrating that these two LPS-responsive
genes are subjected to miRNA-mediated regulation. Most im-
portantly, Fig. 7 D and F shows that stimulation of monocytes with
LPS for only 2 h is not sufﬁcient per se to promote a consistent
recruitment of IκBζ and TNF-α mRNAs to the RISC complex. In
fact, in the absence of miR-187 (i.e., in monocytes transfected with
miR-scr and stimulated for 2 h with LPS), recruitment of IκBζ and
TNF-α mRNAs to the Ago complex is absent or negligible (Fig. 7
D and F). In contrast, both IκBζ and TNF-α mRNAs are strongly
and signiﬁcantly recruited to the RISC complexes only when ex-
ogenous miR-187 is present (Fig. 7 D and F). These data dem-
onstrate that the simultaneous presence of miR-187 with IκBζ and
TNF-α mRNAs in the Ago complexes is not casual; rather, miR-
187 is required to recruit IκBζ and TNF-α mRNAs. This crucial
point is supported further by the analysis of the recruitment of IL-6
and IκBα, mRNAs (which do not contain a miR-187 seed region in
their 3′UTRs) to the RISC complex under the same experimental
Fig. 6. LPS-induced IL-6 and IL-12p40 expression and production are reduced by miR-187–mediated IκBζ knockdown. Monocytes transfected with 150 pmol
miR-scr or miR-187 mimic (A, C, and E) or with 15 pmol si-Ctrl or si-IKBζ siRNA (B, D, and F) were stimulated with LPS for 3 h and then were processed for ChIP
assay (A and B) or IL-6 and IL-12p40 expression (C and D). (A and B) The ChIP assay was carried out using anti-Pol II antibody and was analyzed by qPCR with
speciﬁc primer pairs amplifying the IL-6 or the IL-12p40 promoters. Data from qPCR are expressed as fold change (FC) over the control sample as described in
Materials and Methods and are displayed as means ± SEM of three independent experiments. *P < 0.05; one-way ANOVA. (C and D) Total RNA was puriﬁed
from the same samples, and the expression of IL-6 and IL-12p40 primary transcript (PT) was analyzed by RT-qPCR. Expression of each gene is reported as fold
change after normalization to the RPL32 housekeeping gene. Data are shown as means ± SEM (n = 5). **P < 0.01; one-way ANOVA. (E and F) Antigenic IL-6
(E and F, Left) and IL-12p40 (E and F, Right) levels were determined by ELISA in cell-free supernatant collected 24 h after stimulation with LPS.
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conditions. IL-6 and IκBα mRNA are present in the Ago immu-
noprecipitate in monocytes stimulated with LPS (Fig. 7G and Fig.
S8D), indicating that these mRNA likely are subjected to miRNA-
mediated regulation. However, this event occurs to the same
extent in both the absence (miR-scr) and presence of miR-187
(Fig. 7H and Fig. S8E), demonstrating that the recruitment of
IL-6 and IκBα mRNAs to the RISC complex is not speciﬁcally
dependent on miR-187. The absence of IL-12p40 mRNA (Fig.
7 I and J) and of the ribonucleoprotein 32 (RPL32) mRNA (Fig.
S8 F and G) in Ago immunoprecipitates from LPS-stimulated
monocytes demonstrates that these two mRNAs are not subjected
to posttranscriptional regulation. It also excludes the possibility
that the observed increase in IκBζ, TNF-α, IL-6, and IκBα
mRNAs (Fig. 7 C–H and Fig. S8 D and E) is caused by a general,
nonspeciﬁc enrichment of mRNAs in Ago immunoprecipitates.
Collectively, these data clearly demonstrate that miR-187 post-
transcriptionally regulates NFKBIZ and TNFA gene expression by
driving the physical association of IκBζ and TNF-α mRNAs to the
RISC complex.
miR-187 Expression Is Up-Regulated in Circulating Monocytes Puriﬁed
from Septic Patients. To verify whether miR-187 undergoes in vivo
modulation, miR-187 expression levels were analyzed in pe-
ripheral blood mononuclear cells (PBMC) freshly puriﬁed from
ﬁve patients affected by sepsis. Fig. 8 shows that PBMC from
septic patients, unlike PBMC from healthy donors, constitutively
express high levels of miR-187. Similarly, other miRNAs, namely
miR-155, miR-146a, and miR-9, were found to be constitutively
up-regulated in septic PBMC compared with PBMC from
healthy controls, but miR-21 and let-7a were not (Fig. 8).
Discussion
Negative regulation of inﬂammation is promoted strongly by IL-
10, which primarily inhibits the production of proinﬂammatory
cytokines by activated leukocytes, acting both at the transcrip-
tional and posttranscriptional levels (6). To gain insights into the
posttranscriptional mechanisms whereby IL-10 dampens innate
immune cell activation, we investigated the effects of this anti-
inﬂammatory cytokine on the expression of miRNAs, which have
been shown to have an important role in tuning the inﬂammatory
response by targeting mRNA translation, processing, and stability
(7). This analysis led to the identiﬁcation of miR-187 as an
miRNA induced in an IL-10–dependent manner in activated hu-
man monocytes. Interestingly, freshly puriﬁed mouse bone mar-
row mononuclear cells, BMDM, TEM, and the Raw264.7 mouse
macrophage cell line do not up-regulate miR-187 expression in
response to LPS or LPS plus IL-10, further emphasizing that
species-speciﬁc mechanisms of miRNA-mediated control of TLR
responses have evolved.
IL-10 alone is a relatively weak stimulus, but it strongly syn-
ergizes with LPS in inducing miR-187 expression. Several lines of
evidence clearly point to the requirement for endogenous IL-10
in the induction of miR-187 expression in LPS-activated human
monocytes. (i) LPS, Pam3Cys, and IL-1β fail to up-regulate miR-
187 expression when signaling from endogenous IL-10 is blocked
with anti–IL-10 or anti–IL-10R antibodies. (ii) LPS does not up-
regulate miR-187 expression in human PMN because of its in-
ability to trigger endogenous IL-10 production by these cells
(21). Nevertheless, addition of exogenous IL-10 restores the
ability of PMN to up-regulate miR-187 expression. (iii) Likewise,
miR-187 expression is not induced in monocytes activated by
stimuli that do not trigger IL-10 production, such as the TLR3-
agonist polyinosinic:polycytidylic acidor the proinﬂammatory
cytokine TNF-α. (iv) IL-10 directly potentiates LPS-induced
miR-187 transcription, as shown by the increase in the levels of
premiR-187 expression and by the recruitment of Pol II to the
premiR-187–encoding region, which is abolished in the presence
of IL-10–blocking antibodies.
Analysis of the phenotypic consequences of silencing miR-187
expression provided evidence for the role of this miRNA in the
suppressive activity of IL-10 on LPS-stimulated monocytes. In
Fig. 7. IκBζ and TNF-α mRNA speciﬁcally colocalize with miR-187 in Ago
complexes. Freshly puriﬁed monocytes were left untreated or were stimu-
lated with LPS for 16 h (A, C, E, G, and I) or were transfected with miR-scr or
miR-187 mimic and were stimulated with LPS for 2 h (B, D, F, H, and J). Cells
were lysed for RIP assay and subjected to Ago or IgG (control) immunopre-
cipitation in parallel, as described inMaterial and Methods. The levels of the
indicated miRNAs or mRNAs, as well as input samples, were assayed in
triplicate by RT-qPCR in RIP, are expressed as normalized fold enrichment
(FC) as described in Material and Methods, and are displayed as the mean ±
SEM of four independent experiments for each panel. Asterisks indicate
a statistically signiﬁcant (P < 0.05) difference between LPS-stimulated vs.
resting monocytes or miR-187– vs. miR-scr–transfected monocytes as de-
termined by Student t test; ns, P > 0.05.
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fact, when miR-87 is silenced, the production of LPS-induced
TNF-α, IL-6, and IL-12p40, but not IL-1β, IL-1ra, IFN-β,
CXC10, CCL2, CXC8, and IL-10, is increased signiﬁcantly. In
particular, no modiﬁcation in the levels of LPS-induced IL-10
secretion results from miR-187 silencing, indicating that TNF-α,
IL-6, and IL-12p40 inhibition is not secondary to increased IL-10
production. Most importantly, miR-187 blockade reverses the
IL-10 inhibitory effect on LPS-induced TNF-α, IL-6, and IL-
12p40 production only partially (ranging from 30–50%), in
agreement with data showing that the impact of miRNAs on the
protein output typically is less than 50% (32). Consistent with the
results obtained in miR-187–silenced monocytes, ectopic ex-
pression of miR-187 signiﬁcantly reduces the levels of LPS-
induced TNF-α, IL-6, and IL-12p40 production. Reduction of
cytokine production by miRNAs in vitro, although relatively
small, has been shown to be functionally relevant in physiologic
conditions. For instance, knockdown or overexpression of miR-
155 in Raw264.7 macrophages stimulated in vitro with LPS
modiﬁes the release of proinﬂammatory cytokines from 10% to
50% (17). Despite this modest impact on proinﬂammatory cy-
tokine release, miR-155 has profound physiologic effects and has
been shown to impact the severity of sepsis in a murine model of
endotoxemia (17). Similarly, the potential relevance of miR-187–
mediated effects as a physiological mechanism triggered during
monocyte activation in vivo is supported by the observation that
miR-187 expression is induced at high levels in septic patients. In
fact, we report that circulating PBMC puriﬁed from patients
affected by sepsis constitutively express miR-187 as well as the
already described miR-155 and miR-146a. Therefore it is likely
that miR-187 is induced in monocytes by IL-10, which, along
with other mediators, is known to be produced systemically
during sepsis (33), presumably as part of a circuit to help at-
tenuate the proinﬂammatory state. These observations represent
evidence that an miRNA is actively involved in the anti-in-
ﬂammatory functions of IL-10.
Inspection of Miranda and TargetScan identiﬁed TNF-α
among the potential miR-187 target genes. The presence of
a functional miR-187 seed region regulating TNF-α expression
was validated experimentally by down-modulation of the lucif-
erase-reporter genes containing the wild-type TNF-α 3′UTRs,
but not the mutated form, in an HEK293 cell line overexpressing
miR-187. Analysis of the mechanisms whereby miR-187 inter-
feres with TNF-α production revealed that miR-187 directly
recruits TNF-α mRNA to the RISC complex, thereby promoting
its degradation. Consistently, TNF-α already has been described
as subjected to miRNA-mediated posttranscriptional regulation.
MiR-16 (34), miR-369–3 (35), miR-125b (36, 37), miR-579, and
miR-221 (37) were shown to be involved in the regulation of
TNF-α production in different cellular systems. Nevertheless,
miR-369–3 and miR-579 are not detectable in resting or activated
monocytes (threshold cycle >35) and therefore can be excluded
from playing a role in IL-10–mediated inhibition of TNF-α ex-
pression. Conversely, miR-16, miR-125b and miR-221, although
not modulated by LPS or LPS plus IL-10, are constitutively
expressed in resting monocytes and might take part in the post-
transcriptional modulation of TNF-α expression. However, the
observations that TNF-α mRNA is recruited to the RISC com-
plex only when miR-187 is present and that TNF-α mRNA half-
life is reduced signiﬁcantly only in monocytes overexpressing
miR-187 demonstrate that miR-187 is required for the control of
TNF-α mRNA expression in LPS-stimulated cells.
Even though they are not listed among the putative miR-187
target genes, IL-6 and IL-12p40 expression is signiﬁcantly down-
modulated by miR-187in LPS-treated monocytes. This down-
modulation is achieved by miR-187–driven targeting of NFKBIZ,
a gene encoding for a positive transcriptional regulator of IL-6
and IL-12p40 expression (28). Indeed, in agreement with pre-
vious ﬁndings (29), si-RNA–mediated silencing of IκBζ, the
NFKBIZ gene product, dose-dependently reduces IL-6 and IL-
12p40 production in response to LPS. Moreover, up-regulation
of IκBζ expression by Toll/IL1R activation has been shown to be
controlled by transcriptional (28, 38), posttranscriptional (38,
39), and miRNA-mediated mechanisms (30). Finally, and con-
sistent with published data (40), LPS-induced IκBζ protein ex-
pression is inhibited by IL-10, with kinetics that displayed an
inverse relationship with that of miR-187 expression. In silico
analysis showed a very favorable and low-energy interaction of
the miR-187:NFKBIZ mRNA pair, and overexpression of miR-
187 reduces both the activity of the NFKBIZ-3′UTR-luciferase
reporter in HEK293 cells and the levels of endogenous IκBζ
expression in monocytes. Most importantly, blocking miR-187
expression with miR-187 inhibitor partially reversed IL-10–
mediated inhibition of IκBζ expression, indicating that IκBζ in-
hibition is achieved via up-regulation of miR-187. Therefore, as
a result of miR-187–mediated reduction of IκBζ, the transcrip-
tional activation, but not mRNA stability, of IL-6 and IL-12p40
was diminished, ultimately leading to their reduced production
and secretion.
Collectively, our data identify the miRNA system as a candi-
date mechanism through which IL-10 can tailor monocyte
responses to LPS. Supporting this view, recent data conﬁrmed
herein demonstrate that IL-10 contributes to switching off the
Fig. 8. miR-187 is overexpressed in PBMC from patients with SIRS. The ex-
pression of miR-187, miR-155, miR-9, miR-146a, miR-21, and let-7a was an-
alyzed by RT-qPCR and analyzed as described in Material and Methods in
PBMC freshly puriﬁed from ﬁve healthy donors (■) and from ﬁve SIRS
patients (●). Horizontal bars represent the mean values of relative expres-
sion within each group. **P < 0.01; *P < 0.05; ns, P > 0.05.
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inﬂammatory response by inhibiting LPS-induced expression of
miR-155 (18). In doing so, IL-10 reverses miR-155–mediated
down-regulation of SHIP1, a validated target of miR-155, thus
favoring the negative regulation of TLR4 signaling by counter-
acting PI-3K activity (18). Remarkably, our data demonstrate
that the modulation of LPS responses goes beyond IL-10’s ca-
pacity merely to downmodulate LPS-induced miR-155, in that
we show that IL-10 transiently increases the rate of expression of
LPS-induced miR-146b at early time points and consistently is
required to enhance the expression of miR-187. miR-146b has
been identiﬁed recently as being among miRNAs playing a role
in the resolution phase of inﬂammation (41). In a mouse model
of self-limited acute inﬂammatory response and in human mac-
rophages, miR-146b has been shown to be up-regulated speciﬁ-
cally by resolvin D1, a lipid mediator with anti-inﬂammatory
properties, and to decrease the protein levels of the proin-
ﬂammatory chemokines CXC8 and CCL5 by targeting NF-κB
signaling (41). In this context, we speculate that IL-10, by in-
ducing a rapid increase of miR-146b expression, anticipates the
onset of the physiological resolution of inﬂammation. This issue
is currently under investigation. Finally, and most importantly,
we identify miR-187 as an IL-10–dependent miRNA and provide
mechanistic insight into the role of miR-187 in mediating some
of the IL-10 anti-inﬂammatory activities. MiR-187, induced by
IL-10 endogenously produced by LPS-stimulated monocytes or
present in the inﬂammatory microenvironment, acts as a feedback
modulator of LPS response by directly limiting TNF-α production
at a posttranscriptional level and by reducing IL-6 and IL-12p40
transcription via silencing the transcription factor IκBζ.
Given the widely accepted links between inﬂammation and the
pathogenesis of several diseases, ranging from autoimmune to
neoplastic, the molecular events involved in the development
of inﬂammation-driven pathologies are of obvious importance.
Hence, the identiﬁcation of anti-inﬂammatory miRNAs and the
characterization of their contribution to the resolution phase of
inﬂammation are of considerable interest and might help in the
development of miRNA-targeting drugs.
Materials and Methods
Materials. A detailed list of materials is provided in SI Materials and Methods.
Cell Puriﬁcation and Culture. Human PMN (∼99.7%) and monocytes (∼98.5%)
were puriﬁed from buffy coats of healthy donors by negative magnetic se-
lection and were cultured as described in SI Materials and Methods. The
HEK293 and the Raw264.7 cell lines were grown in DMEM supplemented
with 10% (vol/vol) FCS, 100 U/mL penicillin/streptomycin, and 2 mM L-glu-
tamine. MDM were differentiated from monocytes cultured for 6 d in the
presence of 100 ng/mL macrophage colony-stimulating factor.
Mouse fresh bone marrow mononuclear cells, BMDM, and TEM were
obtained from 8-wk-old wild-type C57BL/6 mice and were differentiated and
cultured as previously described (42, 43).
PBMC were puriﬁed as described in SI Materials and Methods from ﬁve
healthy donors and from ﬁve patients fulﬁlling the criteria of systemic
inﬂammatory response syndrome (SIRS) according to ref. 44. For addi-
tional details, refer to SI Materials and Methods.
miRNA and Gene-Expression Analysis. High-throughput and single-miRNA ex-
pression analyses were performed by TaqMan as previously described (12) and
as described in detail in SI Materials and Methods. The expression of premiR-
187, IL-6, and IL-12p40 primary transcript, IκBζ, TNF-α, IL-6, IL-12p40, and RPL32
mRNA was quantiﬁed by RT-qPCR as previously described (4), using speciﬁc
primer pairs listed in Table S4. RT-qPCR data were normalized to the expres-
sion of the housekeeping gene RPL32.
Constructs and Luciferase Reporter Assays. Renilla luciferase reporter construct
containing the full-length sequence of NFKBIZ 3′ UTR (luc-NFKBIZ) was pur-
chased from SwitchGear Genomics. The other reporter constructs were gener-
ated as described in SI Materials and Methods by primers listed in Table S4.
Transfection of HEK293 cells and the luciferase assay are detailed in SI Materials
and Methods.
Immunoblots. Preparation of cell lysates and Western blot analysis were
conducted as described in detail in SI Materials and Methods. The blots
were incubated with anti-IκBζ, anti-STAT3, or anti-IκBα antibodies, and
detection was performed and quantiﬁed using the Odyssey Infrared Im-
aging System (LI-COR Biosciences).
Monocyte Transfection. Freshly puriﬁedmonocytes (107) were transfected with
the indicated amount of miRNA mimic (Ambion, Applied Biosystems), miR-
CURY LNA miRNA Power Inhibitor (Exiqon), or onTARGETplus siRNA (Dhar-
macon) using the Amaxa Nucleofector and the HumanMonocyte Nucleofector
kit (Amaxa) according to the manufacturer’s protocol. Transfected cells were
stimulated 18 h later as indicated.
ChIP Assay. ChIP experiments were performed as described elsewhere (45).
Brieﬂy, sheared chromatin from 5 × 106 monocytes was immunoprecipitated
overnight at 4 °C using polyclonal antibodies against Pol II (Santa Cruz
Biotechnology). Puriﬁed DNA was analyzed by qPCR in triplicates, using
promoter-speciﬁc primers (Table S4). Data are expressed as described in SI
Materials and Methods.
Ribonucleoprotein Immunoprecipitation and Ago-Associated mRNA Analysis.
Ribonucleoprotein immunoprecipitation (RIP) experiments were performed
as described elsewhere (46), with minor modiﬁcations, as detailed in SI
Materials and Methods. The levels of coimmunoprecipitated miR-187 and
miR-16 and of IκBζ, TNF-α, IL-6, IL-12p40, and RPL32 mRNA then were
assessed by RT-qPCR as described in the previous sections. Sequences of
mRNA-speciﬁc primers used in qPCR are listed in Table S4.
Detection of Cytokine Release. Cytokine concentrations in cell-free super-
natants were measured by speciﬁc human ELISA kits for IL-6 and CXC8
(ImmunoTools), TNF-α, CXC10, CCL2, IL-12p40, and IL-1ra (R&D Systems),
IFN-β (PBL Interferon Source), and IL-1β and IL-10 (e-Biosciences) according
the manufacturers’ instructions.
Statistical Analysis. Statistical evaluation was determined using the Student t
test or one-way ANOVA with power of test set to 0.05. The pairwise multiple
comparison procedures were performed according the Holm–Sidak method,
and P values less than 0.05 were considered signiﬁcant.
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